Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR).
Phase:
PHASE2
Details
Lead Sponsor:
Xiangdong Cheng
Collaborators:
Liaoning Cancer Hospital & Institute Shanxi Province Cancer Hospital Sichuan Cancer Hospital and Research Institute The Second Affiliated Hospital of Harbin Medical University